<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141028</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C</dc:title>
<dc:description xml:lang="en">Background and objective: We analyzed baseline and kinetic characteristics of lipid metabolism during the first month of bitherapy in patients with chronic hepatitis C genotype 1 (CHC-1). Patients and methods: A longitudinal, prospective study including 99 naïve CHC-1 patients with liver biopsy who were treated with bitherapy. Our patients were assigned to one of 5 different &#147;degrees of lipid requirement&#148; that we established depending on the degree of liver fibrosis, baseline viral load and infectivity ratio (ratio between the median level of triglycerides and high densitity lipoproteins-cholesterol during the first month). The goal was to achieve 'a favorable lipid metabolism' (FLM) by establishing a necessary minimum level of low density lipoproteins (LDL)-cholesterol during this period for each one of them. We also analyzed the relationship with the rate of sustained virological response. Results: Patients with liver fibrosis F3-F4 who had higher baseline levels of LDL-cholesterol achieved higher rates of sustained virological response. Those patients who had a lower value of infectivity ratio and median levels of LDL-cholesterol during the first month of bitherapy also achieved higher rates of sustained virological response: SVR group 100 (23) mg/dl against non-SVR group: 89 (28) mg/dl; odds ratio 1.1; 95% confidence interval (1.0-1.2); P &lt; .05, these differences being more significant for genotype IL-28B-CC (P = .013). Patients with sustained virological response had higher rates of FLM. Conclusions: Not every patient with CHC-1 has the same lipid kinetics during the first month of bitherapy, and it is necessary to achieve a sustained virological response and/or a FLM to keep higher plasma levels of LDL-cholesterol during this period. Those subjects without FLM could benefit from statins (AU)</dc:description>
<dc:creator>Barrero Alor, Fátima</dc:creator>
<dc:creator>Germán Casado Monge, Pedro</dc:creator>
<dc:creator>Pujol de la Llave, Emilio</dc:creator>
<dc:creator>Ruíz-Frutos, Carlos</dc:creator>
<dc:creator>Ramos Lora, Manuel</dc:creator>
<dc:creator>Manuel Jiménez Macías, Fernando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivo: Valorar el metabolismo basal y cinético de las lipoproteínas durante el primer mes de biterapia en pacientes con hepatitis crónica C genotipo 1 (HCC-1). Pacientes y métodos: Estudio longitudinal, prospectivo, que incluyó 99 pacientes HCC-1 naive, biopsiados y tratados con biterapia. Clasificamos a nuestros pacientes en 5 niveles de exigencia lipídica, según el grado de fibrosis hepática, carga viral basal y ratio de infectividad (cociente entre concentraciones medias de triglicéridos y colesterol unido a lipoproteínas de alta densidad durante el primer mes), estableciendo para cada uno de ellos, durante este período, una concentración media mínima necesaria de colesterol unido a lipoproteínas de baja densidad (colesterol LDL) para que el paciente alcanzara un «metabolismo lipídico favorable» (MLF), y valoramos su relación con las tasas de curación. Resultados: Alcanzaron mayores tasas de curación aquellos pacientes con fibrosis F3-F4 que presentaron mayores concentraciones basales de colesterol LDL, así como aquellos que consiguieron mantener durante el primer mes de biterapia una ratio de infectividad menor de 3,2 y mayores concentraciones medias de colesterol LDL: media (DE) de 100 (23) mg/dl en «curados» frente a 89 (28) mg/dl en «no curados»,odds ratio 1,1, intervalo de confianza del 95% (1,0-1,2) (p &lt; 0,05), siendo más significativas estas diferencias en los genotipos IL-28B-CC (p = 0,013). Aquellos que alcanzaron la respuesta virológica sostenida presentaron mayores tasas de MLF. Conclusiones: No todos los pacientes con HCC-1 van a presentar durante el primer mes de tratamiento una cinética lipídica favorable, siendo necesario para curarse y/o alcanzar un MLF mantener durante este período unas concentraciones plasmáticas medias de colesterol LDL mayores. Aquellos con ausencia de un MLF podrían beneficiarse del uso de estatinas (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);144(12): 536-543, jun. 2015. tab, graf</dc:source>
<dc:identifier>ibc-141028</dc:identifier>
<dc:title xml:lang="es">Cinética lipídica en el tratamiento antiviral dual en pacientes con hepatitis crónica C</dc:title>
<dc:subject>^d30351^s22062</dc:subject>
<dc:subject>^d30351^s22053</dc:subject>
<dc:subject>^d30351^s22044</dc:subject>
<dc:subject>^d8248</dc:subject>
<dc:subject>^d11547^s22031</dc:subject>
<dc:subject>^d8276^s22053</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d11547^s22033</dc:subject>
<dc:subject>^d8228^s22033</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d8228^s22031</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d24852^s22039</dc:subject>
<dc:subject>^d8276^s22044</dc:subject>
<dc:subject>^d23143</dc:subject>
<dc:subject>^d8248^s22000</dc:subject>
<dc:subject>^d35251</dc:subject>
<dc:subject>^d28320^s22048</dc:subject>
<dc:subject>^d24852^s22045</dc:subject>
<dc:subject>^d28320^s22045</dc:subject>
<dc:subject>^d8248^s22015</dc:subject>
<dc:subject>^d30351^s22016</dc:subject>
<dc:subject>^d8248^s22078</dc:subject>
<dc:type>article</dc:type>
<dc:date>201506</dc:date>
</metadata>
</record>
</ibecs-document>
